Celgene just hit a major setback with its next blockbuster drug

  • Celgene said Tuesday that the FDA refused to review its multiple sclerosis drug Ozanimod for approval.
  • “Upon its preliminary review, the FDA determined that the nonclinical and clinical pharmacology sections in the NDA were insufficient to permit a complete review,” Celgene said in a news release. NDA is short for new drug application.
  • Ozanimod, if approved, is expected to make as much as $US2 billion in peak sales.
  • Celgene has had a difficult couple of months. In October 2017, the company had a huge earnings flop. The company’s also made two acquisition deals in 2018 so far, but the news hasn’t been enough to excite investors.
  • Celgene’s stock fell as much as 6% in pre-market trading on Wednesday.

Screen Shot 2018 02 28 at 9.15.40 AMMarkets Insider

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.